showed a significant increase of oxidized methionines in apoA-I. 20
21
The SR-B1 P297S mutation affects both HDL and LDL/VLDL protein composition. The 22 increase of apoE in carriers suggests a compensatory mechanism for attenuated SR-B1 23 mediated cholesterol uptake by HDL. Increased methionine oxidation may affect HDL 24 function by reducing apoA-I binding to its targets. The results illustrate the complexity of 25 lipoprotein metabolism that has to be taken into account in future therapeutic strategies 26 aiming at targeting SR-B1. 27 28 29 1. Introduction 1 Numerous studies have shown that plasma high-density lipoprotein cholesterol (HDL-C) 2 levels are inversely associated with risk for cardiovascular disease (CVD) [1, 2, 3] . Since 3 there is a need for alternative interventions alongside LDL-cholesterol lowering drugs, these 4 observations have resulted in the exploration of other targets, such as cholesteryl ester 5 transfer protein (CETP) inhibitors, to raise HDL-C levels [4] . In addition, a central mediator 6 of high-density lipoprotein (HDL) metabolism, the scavenger receptor class B type 1 (SR-7 B1), is being considered as a drug target [5] . SR-B1 is a multi-functional receptor, abundantly 8 expressed in liver and steroidogenic tissues [6] , and a wide array of native and modified 9 lipoproteins has been shown to interact with SR-B1 [7] . Regarding the role of SR-B1 in 10 CVD, it has been shown to protect from diet-induced atherosclerosis in apoE-/-mouse 11 models [8, 9] while SR-B1 deficient mice with high HDL-C, showed increased 12 atherosclerosis and increased expression of inflammatory markers [7] . Consistent with this, it 13 has also been shown that a coding variant for SR-B1 (I179N) caused increased 14 atherosclerosis in LDL-receptor knockout mice on a Western-type diet [10] . In humans, 15 variation at the SCARB1 locus (the gene encoding for SR-B1) has been associated to CVD, 16 albeit in a gender specific way [11, 12, 13] . These findings indicate that a functional SR-B1 17 receptor may be athero-protective and that high HDL-C levels resulting from reduced hepatic 18 clearance, by a less functional SR-B1 receptor, may not be beneficial. In accordance, a recent 19 review concluded that therapies aimed at adjusting the HDL-C levels have so far failed and 20 that modulation of HDL functions may be a better way to achieve therapies that reduces the 21 risk for CVD [14] . This also raises the question whether HDL derived from carriers of 22 SCARB1 mutations itself has detrimental properties. Consistent with this, it has been 23 postulated that genetic variation in SCARB1 may give rise to changes in non-lipid pathways 24 which affects the CVD risk, such as inflammation and endothelial function [12] . 25 
26
In humans, there are three described mutations of SR-B1 that cause increased HDL-C. 27
Heterozygous carriers of the first identified mutation SR-B1 P297S were characterized by 28 increased plasma HDL-C mainly in the larger HDL2 fraction while other lipoprotein fractions 29 were consistent with the controls, macrophages with impaired capacity to promote cholesterol 30 efflux to normal HDL, altered platelet function and attenuated adrenal function but without 31 apparent effects on atherosclerosis [15] . The other two mutations, SR-B1 S112F and SR-32 B1 T175A , occupying the same extracellular loop as SR-B1 P297S , are also suggested to be less 33 efficient in mediating cholesterol efflux [16] . Interestingly, also in patients with these two 1 mutations, clinically observed accelerated atherosclerosis was not found [17] . In summary, 2 the alterations in SR-B1 of all three mutations caused elevated HDL-C but to our knowledge, 3 data is still limited regarding possible metabolic consequences. Investigating the lipoprotein 4 composition of subjects with functional mutations in the SR-B1 receptor may be a useful tool 5 for improved understanding. Therefore, we have in the present study investigated the protein 6 composition of HDL and LDL/VLDL and the function of HDL from the heterozygous 7 carriers of the SR-BI P297S mutation and from family controls. 8 9
Materials and Methods

10
Plasma measurements 11
Plasma from SR-B1 P297S heterozygotes and matched family controls, previously identified by 12 screening for individuals with high HDL-C values [15] , was collected in EDTA-tubes after an 13 overnight fast. Total cholesterol and triglycerides levels were measured using standard 14 assays. ApoA-I concentration was determined using a commercially available assay (Randox, 15 Wako) on a COBAS MIRA analyzer. HDL-C was measured as cholesterol remaining after 16 precipitation of apolipoprotein (apo) B-containing lipoproteins. Plasma was frozen 17 immediately in different aliquots for different analyses and was thawed once before use and 18
was not re-used for other purposes. Informed consent was obtained from all subjects and the 19 study was approved by the ethics committee of the Academic Medical Center in Amsterdam. 20 21
HDL and LDL/VLDL isolation 22
HDL and LDL/VLDL isolation of six SR-B1 P297S heterozygotes (2 males and 4 females, age 23 range 21-67 years) and six family controls (3 males and 3 females, age range 39-78 years) 24 was performed by ultracentrifugation as described [18] . Briefly, plasma was isolated from 25 blood samples collected in EDTA by centrifugation for 10 min in 700g at room temperature. 26 EDTA (1mg/mL) and sucrose (5mg/mL) were added to prevent LDL/HDL oxidation and 27 aggregation. Five mL of EDTA-plasma was adjusted to a density of 1.24 g/mL with solid 28
KBr. The plasma samples were layered in the bottom of a centrifuge tube and were gently 29 overlayered with KBr/PBS with a density of 1.063 g/mL. The first ultracentrifugation step 30 was performed at 290 000g for 4h at 15°C. HDL, located in the middle of the KBr/PBS 31 solution and LDL/VLDL located at the top of the tube were then collected with a syringe. An 32 additional centrifugation step was performed for 2h in KBr/PBS solution with a density of 33 1.24 g/mL. The HDL and LDL/VLDL fractions were again collected from the tube with a 1 syringe. All fractions were desalted and protein concentrations were measured with the Bio-2 Rad protein assay (Bio-Rad, Hercules, CA, USA). Samples were lyophilized prior to 2-DE 3 analysis. 4 5 2.3. Proteins were separated on 2-D gels as described previously [19] . Briefly, 400 µg HDL or 7 300 µg LDL/VLDL proteins were isoelectrically focused on immobilized pH gradient strips 8 (pH 3-10) at 46 000 Vh (max 8 000 V), then separated overnight on homogenous (T=14, 9 C=1.5%) gels and fixed and detected by fluorescent SYPRO Ruby protein stain (Bio-Rad). 10 Gel images were evaluated using PDQuest 2-D gel analysis software, v. 7.1.0 (Bio-Rad). 11
Protein abundance was expressed as percent of total 2-D gel fluorescence, multiple isoforms 12 of proteins added together. 13 14
Mass spectrometry 15
Protein spots detected on 2-D gels were map-matched [18] and identified with mass 16 spectrometry. Spots were excised manually and subjected to in-gel trypsin digestion. Peptides 17 were analysed with MALDI-TOF MS (Voyager DE PRO, Applied Biosystems, Foster City, 18 CA, USA). Peptides were mixed 1:1 with matrix (2,5-dihydroxybenzoic acid) in 70% 19 acetonitrile/0.3% trifluoracetic acid (20 mg/mL). Databases NCBI, Swiss-Prot, and UniProt 20 were searched using MS-Fit as search engine (http://prospector.ucsf.edu). Search criteria 21 were defined as; isoelectric point, molecular weight, human species, mass tolerance <50 ppm, 22 methionine oxidation, and cysteine modification by carbamidomethylation. 23 24
Western blot of apoL-1 25
For Western blot (WB), 25 µg of HDL proteins were separated with SDS-PAGE and 26 transferred to a PVDF membrane. After blocking 1h (5% milk in tris-buffered saline, TBS) 27 and incubation over night with anti apoL-1 primary antibodies (Abcam, Ab79282, 1:1000 in 28 2% milk in Tween-TBS), the membranes were incubated for 1h with HRP-conjugated 29 secondary antibodies 1:40 000 (2% milk in Tween-TBS) . Proteins were visualised using 30 ECL plus WB detection system (GE Healthcare, Little Chalfont, UK) and X-ray film. The 31 apoL-1 intensity (optical density/mm 2 ) was calculated with ImageLab (version 3.0.1, Bio 32 Rad) and the relative quantity of apoL-1 was expressed as percent of the total apoL-1 33 intensity. 34 1 2.6. FPLC-fractionation and Western spot-blot of apoE 2 Lipoprotein (plasma) fractionations were carried out with equal portions of EDTA plasma 3 from carriers for the SR-BI P297S mutation (n=4) or matched controls (n=4) (total pool of 1 mL 4 respectively). A superose-6 column combined with an ÄKTA explorer 10S system was used 5 for separation of the lipoprotein fractions (GE Healthcare). The buffer flow was 0.3 mL/min 6 using TBS as flow-buffer (50 mM TRIS, 150 mM NaCl, pH 7.4). A total of 35 plasma 7 fractions (1.0 mL each) of plasma from carriers and controls were collected and further 8 processed for apoE Western spot-blot analysis. Spot-blot analysis was carried out using a 96 9 wells casting system with a mounted PVDF membrane. Of each fraction, 0.9 mL was blotted 10 on the PVDF membrane by vacuum suction. Subsequently the PVDF membrane was blocked 11 with PBS/0.05% tween-20/Milk 5% (pH 7.4) for 30 minutes and washed between each 12 incubation step with PBS/0.05% Tween-20 (pH 7.4). The first incubation for 2 hours with 13 goat anti-human apoE antibodies (1:1000, Bioconnect) as primary antibody was followed by 
Measurement of apoA-I methionine oxidations in HDL by LC-MS/MS 24
Desalted HDL obtained by ultracentrifugation, was digested with trypsin (1: 25 25 trypsin:protein ratio) in a sonicator bath for 30 min at 37°C. Peptide solution was dried by a 26 vacuum centrifugation system before resuspension in 0.1% formic acid in dH2O. Peptides 27 were analyzed using a nanoflow liquid chromatography system coupled to an Orbitrap Velos 28 Pro (Thermo Fisher Scientific, Waltham, MA, USA). Separation was performed during a 90 29 min linear increase from 2 to 40% ACN with 0.1% FA. Peptides were analyzed by a data-30 dependent acquisition mode in which spectra were obtained using Fourier Transmission MS 31 (Orbitrap) and the top 20 peaks selected for CID using linear ion trap. Obtained data was 32 processed in MaxQuant v1.5.12 (Max Planck Institute of Biochemistry, Martinsried, 33
Germany) to search against human ApoA-I. Search was performed using 5 ppm mass 34 tolerance for MS and 0.5 Da for MS/MS. Peptides with a false-discovery rate of less than 1% 1 was retained. Variable modifications searched were methionine oxidation and a minimum 2 score of 40 were needed for accepting modified peptides. Results are expressed as average ± 3 SD for the intensity of peptides with methionine oxidations as well as the ratio between 4 modified and unmodified peptides as obtained through the MaxQuant software. 5 6 2.9. Cholesterol efflux capacity (CEC) assay 7
The cholesterol efflux capacity (CEC) of HDL was quantified as previously described [25, 8 26] . In brief, J774 mouse macrophages plated in 48-well plates were labeled with 0. 
Results
5
The SR-B1 P297S mutation was found in a family in a previous study involving screening of 6 individuals with HDL-C above the 95 th percentile [15] . The carriers of the novel mutation 7 showed increased plasma HDL-C and apoA-I as well as slightly decreased apoB compared to 8 their family controls. In the present study, a subgroup of heterozygous SR-B1 P297S carriers 9 and controls were analyzed showing similar differences in plasma lipid and protein levels 10 (Table 1) . For HDL and LDL/VLDL proteomics, 2-DE and mass spectrometry was used and 11 representative protein patterns are illustrated in Figure 1 and protein identities are presented 12
in Table 2 . 13
14
To study differences in SR-B1 P297S heterozygotes compared to wild-type controls, 2-DE 15 protein intensities, plasma lipid/protein data, HDL CEC, PON1 activities and apoA-I 16 methionine oxidations were investigated by multivariate modelling with PLS. Two 17 components were used and the score plot showed a clear separation of the individuals in the 18 two groups along the predictive x-axis (Figure 2A with the greatest score contribution (defined as the average sample contributions in each 20 group), and thereby the most important values for separating the carriers from the controls, 21 were apoE in LDL/VLDL and apoL-1 in HDL (score contribution of 1.05 and 1.17 for the 22 heterozygotes, respectively). As illustrated in figure 2B, these two variables were located 23 close to the heterozygote node in the loading plot. In addition, univariate statistics of the 2-24 DE data showed a significant increase of apoE in the LDL/VLDL and a significant increase 25 of apoL-1 in the HDL fraction ( Table 2, were analyzed by western spot-blot. The analysis showed a pronounced increase of apoE in 31 LDL, while the increase in the less dense HDL fraction and the decrease in the denser HDL 32 fraction of the heterozygotes as compared to the wild-type controls (Figure 4 ) are in 33 accordance with the previously described shift towards larger HDL particles in the 1 heterozygotes. Interestingly, an increase in lipid-free apoE was also found. 2
3
The in vitro anti-oxidative capacity of HDL in SR-B1 P297S carriers and controls were 4 measured by incubating HDL with oxidized LDL and the ability of HDL to inhibit oxidized 5 LDL from forming DCF was measured. There were no significant changes in the anti-6 oxidative capacity of HDL in SR-B1 P297S carriers compared to the controls ( Figure 5A ). The 7
PONase and AREase activities of PON1 were also measured, and consistent with unchanged 8 anti-oxidative capacity, no significant difference between carriers and controls was observed 9
( Figure 5B and 5C) . with methionine oxidations were found; methionine 110, 136 and 172 (including pre-and 13 propeptide). Methionines at positions 136 and 172 showed a significant increase of oxidized 14 peptide intensity as well as the ratio of modified to unmodified peptides for the specific 15 position in SR-B1 P297S heterozygotes compared to wild-type controls (Table 3) . 16
17
The CEC of heterozygote and control HDL was investigated by measuring cholesterol efflux 18 from J774 mouse macrophages. Results showed that HDL from heterozygotes had no 19 significant differences in their CEC, compared to the controls (Figure 6 ). 20
Discussion
21
Here, multivariate modeling in the form of PLS was utilized to investigate differences 22 between controls and SR-B1 P297S heterozygotes regarding LDL/VLDL and HDL proteomics, 23 plasma lipid/protein data, HDL CEC as well as PON1 activity data ( Figure 2 ). The modelling 24 investigates which factors are responsible for separating the groups. The PLS analyses 25 showed that increased levels of apoE in LDL as well as increased levels of apoL-1 in HDL 26 were important for discriminating between heterozygote carriers for SR-B1 P297S and wild-27 type controls. The model also contained plasma lipid/protein data which reflected the 28 apparent increase of apoA-I and HDL-C as well as the decrease of apoB and LDL-C in 29 carriers compared to controls. 30 31 ApoE, being an LDL receptor ligand, mediates the cellular uptake of triglyceride-rich 1 lipoproteins [27] and is regarded to have anti-atherosclerotic and anti-oxidative properties 2 [28] . Interestingly, in the present study, we found an enrichment of apoE in LDL/VLDL from 3 SR-B1 P297S heterozygotes, which is consistent with the previously indicated increase of 4 plasma apoE in heterozygotes from the same family [15] and with SR-B1 mutant mice having 5 elevated levels of apoE in LDL [29] .To further study the apoE distribution in the carriers, the 6 relative distribution of apo E in different plasma fractions was assessed after FPLC size-7 exclusion chromatography. More apoE was found in the LDL fraction while less was present 8 in the HDL3 fraction (smaller more dense HDL particles) compared to the HDL2 fraction 9 (cholesterol loaded, larger less dense HDL particles) in carriers compared to controls ( Figure  10 4), which may be explained by the previously found shift from HDL3 towards HDL2 in the 11 heterozygotes [15] . Interestingly, the FPLC-separation also revealed an increase of lipid-free 12 apoE in the heterozygotes compared to the controls. Free circulating apoE is normally found 13 at very low concentrations in the circulation and it has been proposed that tissues with 14 increased need for cholesterol such as liver and adrenal gland may secrete free apoE to 15 facilitate the SR-B1 mediated cholesterol uptake, a process in which apoE directly binds to 16 SR-B1 and contributes to increased cholesteryl ester uptake from both HDL and LDL [30] . 17
Further supporting these findings, overexpression of apoE in mice has been shown to increase 18 the uptake of cholesterol via SR-B1 [31]. Enrichment of apoE in LDL/VLDL combined with 19 increased free apoE, as found in the present study, may therefore reflect compensatory 20 mechanisms for attenuated cholesterol uptake in the SR-B1 P297S carriers. Also supporting our 21 data, apoC-I in HDL showed a trend towards lower level in the heterozygotes, as well as 22 being the protein with least association to heterozygotes in the multivariate model (largest 23 negative score contribution with -0.33 in the PLS model). ApoC-1 is a known inhibitor of 24 SR-B1 and CETP action [32, 33] and a reduction of apoC-1 may therefore be a consequence 25 of reduced need for inhibition of SR-B1 pathways in carriers. Considering the increase in apo 26 E, the lower LDL/apoB levels and the absence of reported vascular complications in the 27 heterozygotes, future studies should include investigations of apoB/E receptor mediated 28 cholesterol uptake in subjects with functional SR-B1 mutations. 29 30 Interestingly, the multivariate analysis pointed out apoL-1 in HDL as a key component to 31 discriminate heterozygotes from controls regarding lipoprotein patterns. Accordingly, apoL-1 32 was significantly enriched in HDL in the 2-DE patterns from carriers vs controls, The apo L-33 1 increase was then further confirmed by western blots. As illustrated in figure 4, two 37 34 kDa bands of apoL-1 were detected by immunoblotting, probably corresponding to 1 glycosylated and non-glycosylated apoL-1 [34]. The main increase was found to be in the 2 lower, non-glycosylated band. The function of the glycosylation in apoL-1 is not clear, but 3 enzymatic glycosylation in general is known to provide increased solubility, correct folding 4 or increased stability to the protein. The cause for the increase of the non-glycosylated 5 isoform in the SR-B1 P297S heterozygotes is not known but may depend on de-glycosylation, 6 possibly due to increased retention time of apoL-1 in the circulation but may also reflect 7 increased synthesis, with disturbed glycosylation. In addition, a challenging finding was that 8 an additional 25 kDa band was detected only in heterozygotes. This band may represent an 9 enzymatically modified or truncated form of apoL-1 but was not included in the quantitative 10 analysis since the abundance was too low for identification by MS. ApoL-1 is a HDL-11 associated apolipoprotein which has been reported to exert several extra-and intracellular 12 functions in host defence and hemostatic mechanisms [35, 36] . Although previously mostly 13 studied for its role in trypanosomal lysis [37] recent research has shown polymorphisms in 14 apoL-1 associated to an increased risk for CVD [38] . Thus, indicating a possible, but yet to 15 be identified, function for apoL-1 in CVD development. Notably, apoL-1 plasma levels have 16 been found to be significantly increased in patients with primary cholesteryl ester transfer 17 protein (CETP) deficiency [39], a condition that, as the SR-B1 mutation, results in increased 18 HDL-C levels. The apoL-1 containing HDL subpopulation has previously been shown to 19 represent about 10 % of total HDL [36] and apoL-1 has been reported to preferentially 20 associate with the more dense HDL3 fraction [18, 40] . In contrast, the SR-B1 P297S 21 heterozygotes in the present study have a shift towards more large cholesterol loaded HDL2 22 particles [15] but still increased levels of apoL-1. Further studies are warranted to clarify the 23 role of apoL-1 and how enrichment in HDL may affect HDL functionality in SR-BI P297S 24 carriers. 25
Based on the suggestion that mutations in SR-B1 may increase CVD risk by non-lipid 26 pathways [12] , an important aspect to investigate is HDL function where PON1 is a vital 27 component due to its ability to hydrolyze lipid peroxides in LDL [41] . However, in the 28 present study, no differences in anti-oxidative properties of HDL or PONase and AREase 29 activities could be found in SR-B1 P297S carriers compared to controls. These results are 30 consistent with a previous study investigating heterozygous carriers of a CETP deficiency 31 mutation, also with increased levels of HDL-C, where carriers did not show any change in 32 anti-oxidant capacity or PON1 activity as compared to controls [42] . Regarding other factors 33 that may have impact on cholesterol metabolism, we did find significantly increased levels of 1 methionine oxidations at two positions in HDL-apoA-1 of the heterozygotes compared to the 2 controls. Oxidation of methionine 172 have previously been linked to a reduction in Lecithin-3 cholesterol acyltransferase (LCAT) activation [43] as well as reduced ATP-binding 4 cassette sub-family A member 1 (ABCA1) mediated cholesterol efflux [44] . The increased 5 oxidation found in the SR-B1 P297S heterozygotes may result from prolonged retention time of 6 HDL in the circulation, which is a realistic consequence of reduced SR-B1-mediated uptake 7 by the liver and steroidogenic tissues. 8 9
The HDL CEC has been shown to be inversely associated to markers of CVD and may be a 10 better tool for CVD prediction than HDL-C [25, 45] . However, the CEC assay showed that 11 HDL from SR-B1 P297S heterozygotes had similar capacity to accept cholesterol from J774 12 mouse macrophages as the controls, despite increased methionine oxidations in apoA-I. The 13 unaffected cholesterol efflux capacity may be related to other factors such as the apparently 14 increased apoE or possibly apo L-1 that may normalize the total cellular cholesterol uptake, 15 by redirection or facilitation. Investigating apo E abundance as well as cholesterol uptake via 16 other cholesterol accepting receptors in families with functional mutations in SR-B1 would 17 be highly interesting in future studies. 18
19
Limitations of the study 20 SR-B1 P297S is a rare mutation and a major limitation of the study is the small number of 21 samples analyzed. Therefore, we cannot exclude the possibility of false negative results due 22 to limited statistical power. For example, apo C-1, apoA-II, apoE and transthyretin in HDL 23 showed trends towards alterations but were not statistically different from controls. On the 24 other hand, multiplex techniques such as 2-DE invites the presence of false positive results. 25
However, in the case of apoE and apoL-1 this possibility is highly unlikely since the 2-DE 26 results were confirmed by both immunological assays and multivariate statistics. Another 27 limitation is that 2-DE analysis is not optimal for large, hydrophobic, low abundant proteins. Methionine-136 6.4E+7 ± 6.5E+7 17.7E+7 ± 5.5E+7 ** 0.06 ± 0.06 0.20 ± 0.07 ** 
Methionine
